Quantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry (Région Île-de-France).

Quantoom Biosciences S.A. (“Quantoom”), a Belgian biotech with the mission to reinvent mRNA production announces today the opening of a brand-new facility in évry-Courcouronnes (France).

Following the SynHelix acquisition in 2021, Quantoom already had infrastructures in France, part of the Genopole campus, but these were no longer suitable in view of the dazzling development of the NplifyTM product line (DNA production service), whose activities are mainly concentrated in the team France.

The new facilities are 4 times larger than before and can accommodate the increasing number of equipment and collaborators in order to meet the ambitious goals of the company for the upcoming years. Today, Quantoom in France is led by Irina Gbalou and counts 24 collaborators including experts in process innovation, enzyme engineering, bioinformatics, lab automation and bioprocess, as well as support functions such as project managers and supply chain.

Irina Gbalou, Head of Research at Quantoom commented: “With this new infrastructure, Quantoom will be able to further accelerate the NplifyTM project, which consists in providing high-quality grade synthetic DNA in record time. I’m extremely proud of the amazing work the team in France has done so far and can’t wait to see the positive impact it will have on the company’s goals”.

José Castillo, CEO of Quantoom added: “I am thrilled by this new milestone, as it will have a considerable impact on the overall development of NfinityTM the disruptive RNA production platform we have been developing over the last 18 months. Overall, it also contributes to the mission of Univercells (Quantoom’s parent company) of making biologics available and accessible to all.”